Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985279 | 0.89 | MAPK1 (0.40) | TNKSTNKS2NR1H2NR1H3NPC1 | |
| SCHEMBL6647087 | 0.83 | NISCH (0.48) | TNKSTNKS2NR1H2NR1H3NPC1 | |
| Hydrochloric Acid SCHEMBL10464924 | 0.80 | PDE4B (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10554989 | 0.80 | GAA (0.44) | TNKSTNKS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28279252 | 0.80 | ALDH1A1 (0.46) | TNKSTNKS2PARP2NPC1RAB9A | |
| SCHEMBL3635215 | 0.80 | NPC1 (0.44) | TNKSTNKS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13680573 | 0.80 | MAPK1 (0.54) | TNKSTNKS2PARP2NR1H2NR1H3 | |
| SCHEMBL49612 | 0.79 | GAA (0.52) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12581386 | 0.78 | ALDH1A1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8796643 | 0.78 | TYMP (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2024-01-23 | — | — | US | disclosed |
| CN-111655681-B | Heterocyclylamino-substituted triazoles as modulators of Rho-related protein kinases | 莱德克斯制药公共有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2022-11-15 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2017-10-26 | — | — | US | disclosed |
| WO-2016057658-A9 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016057658-A9 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016057658-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057658-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-2677869-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2615918-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012116145-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012037298-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | TNKS 576/4885TNKS2 322/4885PARP2 1815/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | TNKS 400/4885TNKS2 237/4885PARP2 1579/4885 |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | TNKS 400/4885TNKS2 237/4885PARP2 1579/4885 |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | TNKS 443/4885TNKS2 246/4885PARP2 1644/4885 |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | TNKS 769/4885TNKS2 815/4885PARP2 2073/4885 |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | TNKS 400/4885TNKS2 237/4885PARP2 1579/4885 |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | TNKS 3826/4885TNKS2 4160/4885PARP2 2689/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | TNKS 400/4885TNKS2 237/4885PARP2 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.